This drug is selective for mutant protein without affecting wild‐type BRAF, currently in Phase I/II clinical studies for multiple BRAF V600‐mutated solid tumors including melanoma [396], NSCLC, colorectal cancer, and anaplastic thyroid cancer, with both monotherapy and combination therapy with MEK inhibitor trametinib (NCT05668585). This evidence concerns the gene BRAF and thyroid gland undifferentiated (anaplastic) carcinoma.